John Collinge

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8244317/publications.pdf

Version: 2024-02-01

140 papers	16,902 citations	23567 58 h-index	15266 126 g-index
149 all docs	149 docs citations	149 times ranked	11690 citing authors

#	Article	IF	Citations
1	Assessing initial MRI reports for suspected CJD patients. Journal of Neurology, 2022, 269, 4452-4458.	3.6	9
2	Prion protein monoclonal antibody (PRN100) therapy for Creutzfeldtâ€“Jakob disease: evaluation of a first-in-human treatment programme. Lancet Neurology, The, 2022, 21, 342-354.	10.2	38
3	Iatrogenic cerebral amyloid angiopathy: an emerging clinical phenomenon. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 693-700.	1.9	26
4	A high-content neuron imaging assay demonstrates inhibition of prion disease-associated neurotoxicity by an anti-prion protein antibody. Scientific Reports, 2022, 12, .	3.3	2
5	Estimation of the number of inherited prion disease mutation carriers in the UK. European Journal of Human Genetics, 2022, 30, 1167-1170.	2.8	3
6	2.7â€‰Ã… cryo-EM structure of ex vivo RML prion fibrils. Nature Communications, 2022, 13, .	12.8	66
7	Prions of Vertebrates. , 2021, , 707-713.		0
8	Cognitive decline heralds onset of symptomatic inherited prion disease. Brain, 2021, 144, 989-998.	7.6	1
9	Evaluation of plasma tau and neurofilament light chain biomarkers in a 12-year clinical cohort of human prion diseases. Molecular Psychiatry, 2021, 26, 5955-5966.	7.9	30
10	Brazilin Removes Toxic Alpha-Synuclein and Seeding Competent Assemblies from Parkinson Brain by Altering Conformational Equilibrium. Journal of Molecular Biology, 2021, 433, 166878.	4.2	10
11	Structural differences in amyloid-Î² fibrils from brains of nondemented elderly individuals and Alzheimer's disease patients. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	23
12	NT1-Tau Is Increased in CSF and Plasma of CJD Patients, and Correlates with Disease Progression. Cells, 2021, 10, 3514.	4.1	4
13	PrP is a central player in toxicity mediated by soluble aggregates of neurodegeneration-causing proteins. Acta Neuropathologica, 2020, 139, 503-526.	7.7	110
14	Structural effects of the highly protective V127 polymorphism on human prion protein. Communications Biology, 2020, 3, 402.	4.4	5
15	Potential human transmission of amyloid Î² pathology: surveillance and risks. Lancet Neurology, The, 2020, 19, 872-878.	10.2	46
16	Identification of novel risk loci and causal insights for sporadic Creutzfeldt-Jakob disease: a genome-wide association study. Lancet Neurology, The, 2020, 19, 840-848.	10.2	42
17	Highly infectious prions are not directly neurotoxic. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 23815-23822.	7.1	25
18	Spontaneous generation of prions and transmissible PrP amyloid in a humanised transgenic mouse model of A117V GSS. PLoS Biology, 2020, 18, e3000725.	5.6	13

#	Article	IF	Citations
19	Enteral feeding is associated with longer survival in the advanced stages of prion disease. Brain Communications, 2019, 1, fcz012.	3.3	5
20	Genetic Factors in Mammalian Prion Diseases. Annual Review of Genetics, 2019, 53, 117-147.	7.6	63
21	Early neurophysiological biomarkers and spinal cord pathology in inherited prion disease. Brain, 2019, 142, 760-770.	7.6	16
22	Structural features distinguishing infectious ex vivo mammalian prions from non-infectious fibrillar assemblies generated in vitro. Scientific Reports, 2019, 9, 376.	3.3	37
23	PrP-grafted antibodies bind certain amyloid Î²-protein aggregates, but do not prevent toxicity. Brain Research, 2019, 1710, 125-135.	2.2	14
24	The most problematic symptoms of prion disease â€“ an analysis of carer experiences. International Psychogeriatrics, 2019, 31, 1181-1190.	1.0	4
25	Prion Protein as a Toxic Acceptor of Amyloid-Î² Oligomers. Biological Psychiatry, 2018, 83, 358-368.	1.3	66
26	Transmission of amyloid-Î² protein pathology from cadaveric pituitary growth hormone. Nature, 2018, 564, 415-419.	27.8	122
27	Evaluating the causality of novel sequence variants in the prion protein gene by example. Neurobiology of Aging, 2018, 71, 265.e1-265.e7.	3.1	9
28	Reply to: Intrinsic Toxicity of Antibodies to the Globular Domain of the Prion Protein. Biological Psychiatry, 2018, 84, e53-e54.	1.3	4
29	Variant Creutzfeldtâ€“Jakob Disease in a Patient with Heterozygosity at PRNP Codon 129. New England Journal of Medicine, 2017, 376, 292-294.	27.0	127
30	Targeting glutamatergic and cellular prion protein mechanisms of amyloid Î²-mediated persistent synaptic plasticity disruption: Longitudinal studies. Neuropharmacology, 2017, 121, 231-246.	4.1	26
31	A novel prion protein variant in a patient with semantic dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 890-892.	1.9	4
32	Structural variation in amyloid-Î² fibrils from Alzheimer's disease clinical subtypes. Nature, 2017, 541, 217-221.	27.8	528
33	Neuroanatomical correlates of prion disease progression - a 3T longitudinal voxel-based morphometry study. NeuroImage: Clinical, 2017, 13, 89-96.	2.7	8
34	Methods for Molecular Diagnosis of Human Prion Disease. Methods in Molecular Biology, 2017, 1658, 311-346.	0.9	17
35	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics, 2017, 49, 1373-1384.	21.4	783
36	TMEM106B and ApoE polymorphisms in CHMP2B-mediated frontotemporal dementia (FTD-3). Neurobiology of Aging, 2017, 59, 221.e1-221.e7.	3.1	4

#	Article	IF	Citations
37	Soluble AÎ² aggregates can inhibit prion propagation. Open Biology, 2017, 7, 170158.	3.6	11
38	Early microgliosis precedes neuronal loss and behavioural impairment in mice with a frontotemporal dementia-causing CHMP2B mutation. Human Molecular Genetics, 2017, 26, ddx003.	2.9	22
39	Quantitative EEG parameters correlate with the progression of human prion diseases. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1061-1067.	1.9	24
40	Genetic risk factors for the posterior cortical atrophy variant of Alzheimer's disease. Alzheimer's and Dementia, 2016, 12, 862-871.	0.8	93
41	Diagnosing Sporadic Creutzfeldt-Jakob Disease by the Detection of Abnormal Prion Protein in Patient Urine. JAMA Neurology, 2016, 73, 1454.	9.0	25
42	Collinge et al. reply. Nature, 2016, 535, E2-E3.	27.8	3
43	Collinge et al. reply. Nature, 2016, 537, E9-E9.	27.8	1
44	Mammalian prions and their wider relevance in neurodegenerative diseases. Nature, 2016, 539, 217-226.	27.8	193
45	J9â€...Probing huntingtonâ€™s disease phenocopy syndromes with next-generation sequencing. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A78.2-A78.	1.9	0
46	Ex vivo mammalian prions are formed of paired double helical prion protein fibrils. Open Biology, 2016, 6, 160035.	3.6	55
47	Variants of PLCXD3 are not associated with variant or sporadic Creutzfeldt-Jakob disease in a large international study. BMC Medical Genetics, 2016, 17, 28.	2.1	3
48	Physical, chemical and kinetic factors affecting prion infectivity. Prion, 2016, 10, 251-261.	1.8	2
49	Prion-mediated neurodegeneration is associated with early impairment of the ubiquitinâ€“proteasome system. Acta Neuropathologica, 2016, 131, 411-425.	7.7	51
50	Clinical Trial Simulations Based on Genetic Stratification and the Natural History of a Functional Outcome Measure in Creutzfeldt-Jakob Disease. JAMA Neurology, 2016, 73, 447.	9.0	41
51	Frontotemporal dementia caused by CHMP2B mutation is characterised by neuronal lysosomal storage pathology. Acta Neuropathologica, 2015, 130, 511-523.	7.7	79
52	Identification of clinical target areas in the brainstem of prionâ€infected mice. Neuropathology and Applied Neurobiology, 2015, 41, 613-630.	3.2	11
53	Preclinical detection of infectivity and disease-specific PrP in blood throughout the incubation period of prion disease. Scientific Reports, 2015, 5, 17742.	3.3	21
54	A systematic investigation of production of synthetic prions from recombinant prion protein. Open Biology, 2015, 5, 150165.	3.6	39

#	Article	IF	Citations
55	Transmission Properties of Human PrP 102L Prions Challenge the Relevance of Mouse Models of GSS. PLoS Pathogens, 2015, 11, e1004953.	4.7	27
56	A novel and rapid method for obtaining high titre intact prion strains from mammalian brain. Scientific Reports, 2015, 5, 10062.	3.3	51
57	A naturally occurring variant of the human prion protein completely prevents prion disease. Nature, 2015, 522, 478-481.	27.8	144
58	F2-03-04: Genetic risk factors for posterior cortical atrophy. , 2015, 11, P168-P169.		2
59	Neuronal antibodies in patients with suspected or confirmed sporadic Creutzfeldt-Jakob disease: TableÂ1. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 692-694.	1.9	48
60	Rare structural genetic variation in human prion diseases. Neurobiology of Aging, 2015, 36, 2004.e1-2004.e8.	3.1	6
61	Inherited mtDNA variations are not strong risk factors in human prion disease. Neurobiology of Aging, 2015, 36, 2908.e1-2908.e3.	3.1	0
62	Identification of a Compound That Disrupts Binding of Amyloid-Î² to the Prion Protein Using a Novel Fluorescence-based Assay. Journal of Biological Chemistry, 2015, 290, 17020-17028.	3.4	36
63	Iatrogenic CJD due to pituitary-derived growth hormone with genetically determined incubation times of up to 40 years. Brain, 2015, 138, 3386-3399.	7.6	92
64	Evidence for human transmission of amyloid-Î² pathology and cerebral amyloid angiopathy. Nature, 2015, 525, 247-250.	27.8	418
65	Convergent genetic and expression data implicate immunity in Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 658-671.	0.8	173
66	N-terminal Domain of Prion Protein Directs Its Oligomeric Association. Journal of Biological Chemistry, 2014, 289, 25497-25508.	3.4	20
67	Peripheral Administration of a Humanized Anti-PrP Antibody Blocks Alzheimer's Disease AÎ² Synaptotoxicity. Journal of Neuroscience, 2014, 34, 6140-6145.	3.6	68
68	In vitro screen of prion disease susceptibility genes using the scrapie cell assay. Human Molecular Genetics, 2014, 23, 5102-5108.	2.9	29
69	Population Screening for Variant Creutzfeldt-Jakob Disease Using a Novel Blood Test. JAMA Neurology, 2014, 71, 421.	9.0	51
70	Blood Test for Variant Creutzfeldt-Jakob Diseaseâ€"Reply. JAMA Neurology, 2014, 71, 1054.	9.0	0
71	mGlu5 receptors and cellular prion protein mediate amyloid-Î²-facilitated synaptic long-term depression in vivo. Nature Communications, 2014, 5, 3374.	12.8	157
72	R47H TREM2 variant increases risk of typical earlyâ€onset Alzheimer's disease but not of prion or frontotemporal dementia. Alzheimer's and Dementia, 2014, 10, 602.	0.8	94

#	Article	IF	Citations
73	Predictive testing for inherited prion disease: report of 22 years experience. European Journal of Human Genetics, 2014, 22, 1351-1356.	2.8	23
74	Prion neuropathology follows the accumulation of alternate prion protein isoforms after infective titre has peaked. Nature Communications, 2014, 5, 4347.	12.8	126
75	Ascertainment Bias Causes False Signal of Anticipation in Genetic Prion Disease. American Journal of Human Genetics, 2014, 95, 371-382.	6.2	40
76	Frontotemporal dementia and its subtypes: a genome-wide association study. Lancet Neurology, The, 2014, 13, 686-699.	10.2	302
77	Variant Creutzfeldt-Jakob Disease With Extremely Low Lymphoreticular Deposition of Prion Protein. JAMA Neurology, 2014, 71, 340.	9.0	17
78	Gene-Wide Analysis Detects Two New Susceptibility Genes for Alzheimer's Disease. PLoS ONE, 2014, 9, e94661.	2.5	155
79	A Novel Prion Disease Associated with Diarrhea and Autonomic Neuropathy. New England Journal of Medicine, 2013, 369, 1904-1914.	27.0	113
80	The Medical Research Council Prion Disease Rating Scale: a new outcome measure for prion disease therapeutic trials developed and validated using systematic observational studies. Brain, 2013, 136, 1116-1127.	7.6	77
81	Amyloid-Î² nanotubes are associated with prion protein-dependent synaptotoxicity. Nature Communications, 2013, 4, 2416.	12.8	112
82	PrP Antibodies Do Not Trigger Mouse Hippocampal Neuron Apoptosis. Science, 2012, 335, 52-52.	12.6	62
83	The Risk of Prion Zoonoses. Science, 2012, 335, 411-413.	12.6	25
84	O1â€05â€01: Frontotemporal dementia with the C9ORF72 hexanucleotide repeat expansion: Clinical, neuroanatomical and neuropathological features. Alzheimer's and Dementia, 2012, 8, P92.	0.8	0
85	Prion propagation and toxicity in vivo occur in two distinct mechanistic phases. Nature, 2011, 470, 540-542.	27.8	269
86	Molecular pathology of human prion disease. Acta Neuropathologica, 2011, 121, 69-77.	7.7	90
87	Interaction between prion protein and toxic amyloid Î² assemblies can be therapeutically targeted at multiple sites. Nature Communications, 2011, 2, 336.	12.8	263
88	PRNP allelic series from 19 years of prion protein gene sequencing at the MRC Prion Unit. Human Mutation, 2010, 31, E1551-E1563.	2.5	85
89	Pharmacological chaperone for the structured domain of human prion protein. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 17610-17615.	7.1	71
90	Amyloid Î²-Protein Dimers Rapidly Form Stable Synaptotoxic Protofibrils. Journal of Neuroscience, 2010, 30, 14411-14419.	3.6	232

#	Article	IF	Citations
91	Prion Strain Mutation and Selection. Science, 2010, 328, 1111-1112.	12.6	76
92	Isolation of Proteinase K-Sensitive Prions Using Pronase E and Phosphotungstic Acid. PLoS ONE, 2010, 5, e15679.	2.5	34
93	Preventing Prion Pathogenicity by Targeting the Cellular Prion Protein. Infectious Disorders - Drug Targets, 2009, 9, 48-57.	0.8	35
94	Conformational Properties of Î²-PrP. Journal of Biological Chemistry, 2009, 284, 21981-21990.	3.4	34
95	Unswitched immunoglobulin M response prolongs mouse survival in prion disease. Journal of General Virology, 2009, 90, 777-782.	2.9	21
96	Genetic risk factors for variant Creutzfeldtâ€“Jakob disease: a genome-wide association study. Lancet Neurology, The, 2009, 8, 57-66.	10.2	131
97	Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial. Lancet Neurology, The, 2009, 8, 334-344.	10.2	226
98	A Novel Protective Prion Protein Variant that Colocalizes with Kuru Exposure. New England Journal of Medicine, 2009, 361, 2056-2065.	27.0	157
99	Absence of spontaneous disease and comparative prion susceptibility of transgenic mice expressing mutant human prion proteins. Journal of General Virology, 2009, 90, 546-558.	2.9	58
100	Single treatment with RNAi against prion protein rescues early neuronal dysfunction and prolongs survival in mice with prion disease. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 10238-10243.	7.1	174
101	A clinical study of kuru patients with long incubation periods at the end of the epidemic in Papua New Guinea. Philosophical Transactions of the Royal Society B: Biological Sciences, 2008, 363, 3725-3739.	4.0	65
102	Reminiscences and reflections on kuru, personal and scientific. Philosophical Transactions of the Royal Society B: Biological Sciences, 2008, 363, 3613-3613.	4.0	0
103	Lessons of kuru research: background to recent studies with some personal reflections. Philosophical Transactions of the Royal Society B: Biological Sciences, 2008, 363, 3689-3696.	4.0	18
104	Introduction. Philosophical Transactions of the Royal Society B: Biological Sciences, 2008, 363, 3607-3612.	4.0	10
105	Detection and characterization of proteinase K-sensitive disease-related prion protein with thermolysin. Biochemical Journal, 2008, 416, 297-305.	3.7	118
106	Molecular Diagnosis of Human Prion Disease. Methods in Molecular Biology, 2008, 459, 197-227.	0.9	38
107	Targeting Cellular Prion Protein Reverses Early Cognitive Deficits and Neurophysiological Dysfunction in Prion-Infected Mice. Neuron, 2007, 53, 325-335.	8.1	246
108	A General Model of Prion Strains and Their Pathogenicity. Science, 2007, 318, 930-936.	12.6	937

#	Article	IF	Citations
109	Î²-PrP form of human prion protein stimulates production of monoclonal antibodies to epitope 91â€“110 that recognise native PrPSc. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2007, 1774, 1438-1450.	2.3	25
110	Kuru in the 21st centuryâ€”an acquired human prion disease with very long incubation periods. Lancet, The, 2006, 367, 2068-2074.	13.7	345
111	A systematic review of prion therapeutics in experimental models. Brain, 2006, 129, 2241-2265.	7.6	250
112	Elongated Oligomers Assemble into Mammalian PrP Amyloid Fibrils. Journal of Molecular Biology, 2006, 357, 975-985.	4.2	61
113	Distinct glycoform ratios of protease resistant prion protein associated with PRNP point mutations. Brain, 2006, 129, 676-685.	7.6	93
114	Phenotypic heterogeneity in inherited prion disease (P102L) is associated with differential propagation of protease-resistant wild-type and mutant prion protein. Brain, 2006, 129, 1557-1569.	7.6	91
115	Codon 129 polymorphism of the human prion protein influences the kinetics of amyloid formation. Journal of General Virology, 2006, 87, 2443-2449.	2.9	28
116	Dissociation of pathological and molecular phenotype of variant Creutzfeldt-Jakob disease in transgenic human prion protein 129 heterozygous mice. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 10759-10764.	7.1	68
117	An enzymeâ€“detergent method for effective prion decontamination of surgical steel. Journal of General Virology, 2005, 86, 869-878.	2.9	103
118	PrP glycoforms are associated in a strain-specific ratio in native PrPSc. Journal of General Virology, 2005, 86, 2635-2644.	2.9	63
119	Definable Equilibrium States in the Folding of Human Prion Proteinâ€. Biochemistry, 2005, 44, 16649-16657.	2.5	51
120	Characterization of two distinct prion strains derived from bovine spongiform encephalopathy transmissions to inbred mice. Journal of General Virology, 2004, 85, 2471-2478.	2.9	45
121	The Residue 129 Polymorphism in Human Prion Protein Does Not Confer Susceptibility to Creutzfeldt-Jakob Disease by Altering the Structure or Global Stability of PrPC. Journal of Biological Chemistry, 2004, 279, 28515-28521.	3.4	68
122	Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature, 2003, 422, 80-83.	27.8	457
123	Depleting Neuronal PrP in Prion Infection Prevents Disease and Reverses Spongiosis. Science, 2003, 302, 871-874.	12.6	673
124	Balancing Selection at the Prion Protein Gene Consistent with Prehistoric Kurulike Epidemics. Science, 2003, 300, 640-643.	12.6	347
125	Molecular classification of sporadic Creutzfeldtâ€“Jakob disease. Brain, 2003, 126, 1333-1346.	7.6	301
126	BSE prions propagate as either variant CJD-like or sporadic CJD-like prion strains in transgenic mice expressing human prion protein. EMBO Journal, 2002, 21, 6358-6366.	7.8	317

#	Article	IF	Citations
127	Prion Diseases of Humans and Animals: Their Causes and Molecular Basis. Annual Review of Neuroscience, 2001, 24, 519-550.	10.7	1,194
128	HLA-DQ7 antigen and resistance to variant CJD. Nature, 2001, 414, 269-270.	27.8	49
129	Structural mobility of the human prion protein probed by backbone hydrogen exchange. Nature Structural Biology, 1999, 6, 740-743.	9.7	140
130	Variant Creutzfeldt-Jakob disease. Lancet, The, 1999, 354, 317-323.	13.7	483
131	Sequence variation in intron of prion protein gene, crucial for complete diagnostic strategies. Human Mutation, 1996, 7, 280-281.	2.5	13
132	Molecular analysis of prion strain variation and the aetiology of 'new variant' CJD. Nature, 1996, 383, 685-690.	27.8	1,649
133	Tissue Handling in Suspected Creutzfeldtâ€Jakob Disease (CJD) and Other Human Spongiform Encephalopathies (Prion Diseases). Brain Pathology, 1995, 5, 319-322.	4.1	103
134	Clinical features of early onset, familial Alzheimer's disease linked to chromosome 14. American Journal of Medical Genetics Part A, 1995, 60, 44-52.	2.4	9
135	Rescue of neurophysiological phenotype seen in PrP null mice by transgene encoding human prion protein. Nature Genetics, 1995, 9, 197-201.	21.4	141
136	Decreased Hippocampal Expression of a Glutamate Receptor Gene in Schizophrenia. British Journal of Psychiatry, 1991, 159, 857-859.	2.8	23
137	Homozygous prion protein genotype predisposes to sporadic Creutzfeldtâ€"Jakob disease. Nature, 1991, 352, 340-342.	27.8	838
138	CJD discrepancy. Nature, 1991, 353, 802-802.	27.8	9
139	Human Prion Diseases. , 0, , 779-811.		0
140	Human Prion Diseases. , 0, , 939-968.		6